Nabriva Therapeutics plc Research and Development Expense
Nabriva Therapeutics plc reported Research and Development Expense of $1.09 million for the 3-month period ending 2023-06-30, per its 10-Q filed 2023-10-19.
Discontinued › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2023-10-19
- Nabriva Therapeutics plc research and development expense for the quarter ending 2023-06-30 was $1.09M, a 73.43% decline year-over-year.
- Nabriva Therapeutics plc research and development expense for the quarter ending 2023-03-31 was $2.63M, a 25.36% decline year-over-year.
- Nabriva Therapeutics plc research and development expense for the quarter ending 2022-12-31 was $2.63M, a 9.83% increase year-over-year.
- Nabriva Therapeutics plc research and development expense for the quarter ending 2022-09-30 was $4.03M, a 25.18% increase year-over-year.
- Nabriva Therapeutics plc research and development expense for fiscal 2022 was $14.26M, a 12.93% increase from fiscal 2021.
- Nabriva Therapeutics plc research and development expense for fiscal 2021 was $12.63M, a 16.37% decline from fiscal 2020.
- Nabriva Therapeutics plc research and development expense for fiscal 2020 was $15.10M, a 42.83% decline from fiscal 2019.
- Nabriva Therapeutics plc research and development expense for fiscal 2019 was $26.41M, a 67.90% decline from fiscal 2018.
| Period end | Research and Development Expense 3 month | Research and Development Expense 3 month as first filed | Research and Development Expense 6 month | Research and Development Expense 6 month as first filed | Research and Development Expense 9 month | Research and Development Expense 9 month as first filed | Research and Development Expense 12 month |
|---|---|---|---|---|---|---|---|
| 2023-06-30 | $1.09M 10-Q · filed 2023-10-19 | $3.71M 10-Q · filed 2023-10-19 | $6.34M derived: sum of 3 quarters · filed 2023-10-19 | $10.37M derived: sum of 4 quarters · filed 2023-10-19 | |||
| 2023-03-31 | $2.63M 10-Q · filed 2023-05-22 | $5.25M derived: sum of 2 quarters · filed 2023-05-22 | $9.28M derived: sum of 3 quarters · filed 2023-05-22 | $13.37M derived: sum of 4 quarters · filed 2023-10-19 | |||
| 2022-12-31 | $2.63M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $6.66M derived: sum of 2 quarters · filed 2023-04-17 | $10.75M derived: sum of 3 quarters · filed 2023-10-19 | $14.26M 10-K · filed 2023-04-17 | |||
| 2022-09-30 | $4.03M 10-Q · filed 2022-11-10 | $8.12M derived: sum of 2 quarters · filed 2023-10-19 | $11.64M 10-Q · filed 2022-11-10 | $14.03M derived: sum of 4 quarters · filed 2023-10-19 | |||
| 2022-06-30 | $4.09M 10-Q · filed 2023-10-19 | $7.61M 10-Q · filed 2023-10-19 | $10.00M derived: sum of 3 quarters · filed 2023-10-19 | $13.22M derived: sum of 4 quarters · filed 2023-10-19 | |||
| 2022-03-31 | $3.52M 10-Q · filed 2023-05-22 | $5.91M derived: sum of 2 quarters · filed 2023-05-22 | $9.13M derived: sum of 3 quarters · filed 2023-05-22 | $12.28M derived: sum of 4 quarters · filed 2023-05-22 | |||
| 2021-12-31 | $2.39M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $5.61M derived: sum of 2 quarters · filed 2023-04-17 | $8.76M derived: sum of 3 quarters · filed 2023-04-17 | $12.63M 10-K · filed 2023-04-17 | |||
| 2021-09-30 | $3.22M 10-Q · filed 2022-11-10 | $6.37M derived: sum of 2 quarters · filed 2022-11-10 | $10.24M 10-Q · filed 2022-11-10 | $13.08M derived: sum of 4 quarters · filed 2023-04-17 | |||
| 2021-06-30 | $3.15M 10-Q · filed 2022-08-03 | $7.02M 10-Q · filed 2022-08-03 | $9.86M derived: sum of 3 quarters · filed 2023-04-17 | $13.35M derived: sum of 4 quarters · filed 2023-04-17 | |||
| 2021-03-31 | $3.87M 10-Q · filed 2022-05-05 | $6.71M derived: sum of 2 quarters · filed 2023-04-17 | $10.20M derived: sum of 3 quarters · filed 2023-04-17 | $14.03M derived: sum of 4 quarters · filed 2023-04-17 | |||
| 2020-12-31 | $2.84M derived: 10-K 12 month − 10-Q 9 month · filed 2023-04-17 | $6.33M derived: sum of 2 quarters · filed 2023-04-17 | $10.16M derived: sum of 3 quarters · filed 2023-04-17 | $15.10M 10-K · filed 2023-04-17 | |||
| 2020-09-30 | $3.49M 10-Q · filed 2021-11-09 | $7.32M derived: sum of 2 quarters · filed 2021-11-09 | $12.26M 10-Q · filed 2021-11-09 | $14.93M 10-Q · filed 2020-11-05 | $17.46M derived: sum of 4 quarters · filed 2022-03-29 | ||
| 2020-06-30 | $3.83M 10-Q · filed 2021-08-05 | $6.50M 10-Q · filed 2020-08-06 | $8.78M 10-Q · filed 2021-08-05 | $11.44M 10-Q · filed 2020-08-06 | $13.98M derived: sum of 3 quarters · filed 2022-03-29 | $19.58M derived: sum of 4 quarters · filed 2022-03-29 | |
| 2020-03-31 | $4.94M 10-Q · filed 2021-05-06 | $10.15M derived: sum of 2 quarters · filed 2022-03-29 | $15.75M derived: sum of 3 quarters · filed 2022-03-29 | $23.82M derived: sum of 4 quarters · filed 2022-03-29 | |||
| 2019-12-31 | $5.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $10.80M derived: sum of 2 quarters · filed 2022-03-29 | $18.88M derived: sum of 3 quarters · filed 2022-03-29 | $26.41M 10-K · filed 2022-03-29 | |||
| 2019-09-30 | $5.60M 10-Q · filed 2020-11-05 | $13.68M derived: sum of 2 quarters · filed 2020-11-05 | $21.21M 10-Q · filed 2020-11-05 | $42.70M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2019-06-30 | $8.07M 10-Q · filed 2020-08-06 | $15.61M 10-Q · filed 2020-08-06 | $37.10M derived: sum of 3 quarters · filed 2021-03-11 | $77.90M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2019-03-31 | $7.54M 10-Q · filed 2020-05-11 | $29.03M derived: sum of 2 quarters · filed 2021-03-11 | $69.83M derived: sum of 3 quarters · filed 2021-03-11 | $79.55M derived: sum of 4 quarters · filed 2021-03-11 | |||
| 2018-12-31 | $21.49M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $62.29M derived: sum of 2 quarters · filed 2021-03-11 | $72.01M derived: sum of 3 quarters · filed 2021-03-11 | $82.29M 10-K · filed 2021-03-11 | |||
| 2018-09-30 | $40.80M 10-Q · filed 2019-11-12 | $50.52M derived: sum of 2 quarters · filed 2019-11-12 | $60.80M 10-Q · filed 2019-11-12 | $74.04M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-06-30 | $9.72M 10-Q · filed 2019-08-08 | $20.00M 10-Q · filed 2019-08-08 | $33.24M derived: sum of 3 quarters · filed 2020-03-12 | $45.91M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2018-03-31 | $10.28M 10-Q · filed 2019-05-10 | $23.52M derived: sum of 2 quarters · filed 2020-03-12 | $36.19M derived: sum of 3 quarters · filed 2020-03-12 | $47.23M derived: sum of 4 quarters · filed 2020-03-12 | |||
| 2017-12-31 | $13.24M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12 | $25.91M derived: sum of 2 quarters · filed 2020-03-12 | $36.95M derived: sum of 3 quarters · filed 2020-03-12 | $49.62M 10-K · filed 2020-03-12 | |||
| 2017-09-30 | $12.67M 10-Q · filed 2018-11-06 | $23.71M derived: sum of 2 quarters · filed 2018-11-06 | $36.37M 10-Q · filed 2018-11-06 | $49.33M derived: sum of 4 quarters · filed 2019-03-12 | |||
| 2017-06-30 | $11.04M 10-Q · filed 2018-08-09 | $23.70M 10-Q · filed 2018-08-09 | $36.66M derived: sum of 3 quarters · filed 2019-03-12 | $48.72M derived: sum of 4 quarters · filed 2019-03-12 | |||
| 2017-03-31 | $12.66M 10-Q · filed 2018-05-08 | $25.62M derived: sum of 2 quarters · filed 2019-03-12 | $37.67M derived: sum of 3 quarters · filed 2019-03-12 | $47.62M derived: sum of 4 quarters · filed 2019-03-12 | |||
| 2016-12-31 | $12.96M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | $25.02M derived: sum of 2 quarters · filed 2019-03-12 | $34.96M derived: sum of 3 quarters · filed 2019-03-12 | $47.99M 10-K · filed 2019-03-12 | |||
| 2016-09-30 | $12.06M 10-Q · filed 2017-11-09 | $22.00M derived: sum of 2 quarters · filed 2017-11-09 | $35.04M 10-Q · filed 2017-11-09 | ||||
| 2016-06-30 | $9.94M 10-Q · filed 2017-08-07 | $22.98M 10-Q · filed 2017-08-07 | |||||
| 2016-03-31 | $13.04M 10-Q · filed 2017-05-10 | ||||||
| 2015-12-31 | $23.60M 10-K · filed 2018-03-16 |